Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer

Tamoxifen(TAM) is one of the most effective endocrine treatment for estrogen receptor(ER)-positive breast cancer, however drug resistance greatly limits benefit of it. Our purpose is to uncover the role of Beclin 1 in tamoxifen resistance and prognosis of ER positive breast cancer. We established a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Yu, Chen, Tianxiang, Li, Guangliang, Xu, Cong, Xu, Zhenzhen, Zhang, Jing, He, Kuifeng, Zheng, Linyan, Guan, Zhonghai, Su, Xinyun, Cao, Jiang, Teng, Lisong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581020/
https://www.ncbi.nlm.nih.gov/pubmed/28881721
http://dx.doi.org/10.18632/oncotarget.11044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581020/
https://www.ncbi.nlm.nih.gov/pubmed/28881721
http://dx.doi.org/10.18632/oncotarget.11044

Ejemplares similares